Analysis of survival and prognostic differences in locally advanced or metastatic non-squamous non-small cell lung cancer with KRAS mutations.

J Thorac Dis · 2026 · PMC13266823 · PMID 42306742

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the OS benefit of the combined therapy did not reach statistical significance, the favorable trend aligns with previous research, confirming the synergistic value of combined therapy.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.